Company / Net Income
Lineage Cell Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$63.5M
FY2025
5-year range
-$63.5M / -$18.6M
FY2021-FY2025
Trend
-241.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed -241% YoY in FY2025, a notable deviation from the 9-year average annual change of -43%.
Based on SEC 10-K filings.
-$64M in FY2025.
Declined from -$21M to -$64M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 241.4% year-over-year.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$63.5M | -241.4% |
| FY2024 | -$18.6M | +13.4% |
| FY2023 | -$21.5M | +50.1% |
| FY2022 | -$43.0M | -108.3% |
| FY2021 | -$20.6M | -76.4% |
| FY2020 | -$11.7M | +74.5% |
| FY2019 | -$46.0M | -130.2% |
| FY2018 | -$20.0M | +57.5% |
| FY2017 | -$47.0M | -29.1% |
| FY2016 | -$36.4M | +17.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026